Metrics as of 10/16/2026, 08:40 AM (Berlin time), refresh in progress.
IXICO Stock
IXICO plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Bram Goorden
- Employees
- 79
- Market cap
- £17 M
- IPO
- 25/04/1996
- Web
- ixico.com
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and internationally, IXICO supports clinical trials by managing the entire…
IXICO stock: price history
1D
+0.0%
1W
+0.0%
1M
+3.3%
6M
+8.7%
YTD
-34.0%
1Y
-38.0%
2Y
-16.2%
5Y
-90.8%
10Y
-66.3%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~13% weaker price swings than usual
Ask the agents about IXICO
IXICO stock metrics
P/E
-3.95
P/B
0.67
EV/EBITDA
-6.79
RETURN ON EQUITY
-10.5%
NET MARGIN
-28.5%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
64.6%
FLOAT SHARES
141,468,591
AVG. DAILY VOLUME (30D)
51,661
Dividends & Stock splits
Comparable stocks
Frequently asked questions about IXICO stock
What does IXICO do?
IXICO plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Bram Goorden, the company employs around 79 people.
The IPO was on 25/04/1996; the stock trades on LSE under the ticker IXI.L.
When does IXICO report next?
Around past earnings, price swings were roughly -13% stronger than usual.
Does IXICO pay a dividend?
No, IXICO currently does not pay a dividend.
Which stocks are comparable to IXICO?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get IXICO stock analyzed?
Clicking "Analyze stock" lets five strategies assess IXICO against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.